1) Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux
J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J,
Peix JL, Francois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis
from non-gynecologic malignancies: Results of the EVOCAPE 1
multicentric prospective study. Cancer. 2000;88:358-63.
2) Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi
C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, Catena F.
Peritoneal carcinomatosis. World J Gastroenterol. 2013;19:6979-94.
3) Fukuchi M, Mochiki E, Suzuki O, Ishiguro T, Sobajima J,
Onozawa H, Imaizumi H, Shibata K, Saito K, Naitoh H, Kumagai
Y, Ishibashi K, Ishida H. Factors predicting recurrence in patients
with Siewert type II carcinoma treated with curative resection.
Anticancer Res. 2015;35:505-9.
4) Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E,
Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza
C, Paoletti P. Phase III study of pemetrexed in combination with
cisplatin versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 2003;21:2636-44.
5) Kindler HL. Peritoneal mesothelioma: The site of origin matters.
Am Soc Clin Oncol Educ Book. 2013;182-8.
6) Tandon RT, Jimenez-Cortez Y, Taub R, Borczuk AC. Immunohistochemistry
in peritoneal mesothelioma: A single-center experience
of 244 cases. Arch Pathol Lab Med. 2018;142:236-42.
7) Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis
from colorectal cancer. Br J Surg. 2002;89:1545-50.
8) Sugarbaker PH. New standard of care for appendiceal epithelial
neoplasms and pseudomyxoma peritonei syndrome? Lancet
Oncol. 2006;7:69-76.
9) Rogers JH. Calretinin: A gene for a novel calcium-binding protein
expressed principally in neurons. J Cell Biol. 1987;105:1343-53.
10) Cargnello R, Celio MR, Schwaller B, Gotzos V. Change of
calretinin expression in the human colon adenocarcinoma
cell line HT29 after differentiation. Biochim Biophys Acta.
1996;1313:201-8.
11) Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio
MR, Viale G. Calretinin: A novel immunocytochemical marker
for mesothelioma. Am J Surg Pathol. 1996;20:1037-46.
12) Gotzos V, Wintergerst ES, Musy JP, Spichtin HP, Genton CY.
Selective distribution of calretinin in adenocarcinomas of the
human colon and adjacent tissues. Am J Surg Pathol. 1999;23:701-11.
13) Blum W, Schwaller B. Calretinin is essential for mesothelioma
cell growth/survival in vitro: A potential new target for malignant
mesothelioma therapy? Int J Cancer. 2013;133:2077-88.
14) Sato T, Ohwada A, Miyaji A, Miyazaki R, Suzuki M, Matsumoto
T. Immunohistochemistry for the differentiation of peritoneal
disseminated carcinoma of unknown origin. Intern Med.
2004;43:415-9.
15) Foda AA, El-Hawary AK, Hamed H. Aberrant expression of
calretinin, D2-40 and mesothelin in mucinous and non-mucinous
colorectal carcinomas and relation to clinicopathological features
and prognosis. Pathol Oncol Res. 2016;22:725-32.
16) Taliano RJ, Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick
MB, Yakirevich E. Calretinin expression in high-grade invasive
ductal carcinoma of the breast is associated with basal-like
subtype and unfavorable prognosis. Hum Pathol. 2013;44:2743-50.
17) Ruitenbeek T, Gouw AS, Poppema S. Immunocytology of body
cavity fluids. MOC-31, a monoclonal antibody discriminating
between mesothelial and epithelial cells. Arch Pathol Lab Med.
1994;118:265-9.
18) Gander JC, Gotzos V, Fellay B, Schwaller B. Inhibition of the
proliferative cycle and apoptotic events in WiDr cells after
down-regulation of the calcium-binding protein calretinin using
antisense oligodeoxynucleotides. Exp Cell Res. 1996;225:399-410.
19) Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-
31 aids in the differentiation between adenocarcinoma and
reactive mesothelial cells. Cancer. 1999;87:390-4.
20) Shield PW, Koivurinne K. The value of calretinin and cytokeratin
5/6 as markers for mesothelioma in cell block preparations of
serous effusions. Cytopathology. 2008;19:218-23.
21) Kalof AN, Cooper K. D2-40 immunohistochemistry-so far! Adv
Anat Pathol. 2009;16:62-4.
22) Hyun TS, Barnes M, Tabatabai ZL. The diagnostic utility of D2-
40, calretinin, CK5/6, desmin and MOC-31 in the differentiation
of mesothelioma from adenocarcinoma in pleural effusion
cytology. Acta Cytol. 2012;56:527-32.
23) Diop AD, Fontarensky M, Montoriol PF, Da Ines D. CT imaging
of peritoneal carcinomatosis and its mimics. Diagn Interv
Imaging. 2014;95:861-72.
24) Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi
K, Igarashi S. Patterns of recurrence after curative resection of
pancreatic cancer, based on autopsy findings. J Gastrointest Surg.
2006;10:511-8.
25) Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S.
Factors predicting recurrence after resection of pancreatic ductal
carcinoma. Pancreas. 2005;31:69-73.
26) Ordonez NG. Value of mesothelin immunostaining in the
diagnosis of mesothelioma. Mod Pathol. 2003;16:192-7.
27) Ordonez NG, Sahin AA. Diagnostic utility of immunohistochemistry
in distinguishing between epithelioid pleural mesotheliomas
and breast carcinomas: A comparative study. Hum Pathol.
2014;45:1529-40.
28) Ascoli V, Minelli G, Cozzi I, Romeo E, Carnovale Scalzo C,
Ancona L, Forastiere F. Pathology reporting of malignant pleural
mesothelioma first diagnosis: A population-based approach.
Pathol Res Pract. 2016;212:886-92.
29) Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman
D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan
AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR,
Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao
A, Woodard GA, Yang H, Malik S. Consensus report of the 2015
Weinman International Conference on mesothelioma. J Thorac
Oncol. 2016;11:1246-62.
30) Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-
40, a novel mesothelial marker, in the diagnosis of malignant
mesothelioma. Mod Pathol. 2005;18:105-10.
31) Ordonez NG. D2-40 and podoplanin are highly specific and
sensitive immunohistochemical markers of epithelioid malignant
mesothelioma. Hum Pathol. 2005;36:372-80.
32) Muller AM, Franke FE, Muller KM. D2-40: A reliable marker in
the diagnosis of pleural mesothelioma. Pathobiology. 2006;73:50-4.
33) Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin
and other mesothelioma markers in synovial sarcoma: Analysis
of antigenic similarities and differences with malignant
mesothelioma. Am J Surg Pathol. 2001;25:610-7.
34) Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher
M, Storz M, Mihatsch MJ, Sauter G. Calretinin expression in
human normal and neoplastic tissues: A tissue microarray
analysis on 5233 tissue samples. Hum Pathol. 2003;34:994-1000.
35) Winn B, Tavares R, Fanion J, Noble L, Gao J, Sabo E, Resnick
MB. Differentiating the undifferentiated: Immunohistochemical
profile of medullary carcinoma of the colon with an emphasis on
intestinal differentiation. Hum Pathol. 2009;40:398-404.
36) Liu S, Rao D, Hechtman J, Vakiani E, Klimstra D, Shia J. Calretinin
positivity in poorly differentiated colorectal carcinoma: A
diagnostic pitfall. Laboratory Investigation. 2017;97(S1):157-210.
37) Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger
H, Banerjee D, Baumal R. Characterization and distribution of
an oncofetal antigen (M2A antigen) expressed on testicular germ
cell tumours. Br J Cancer. 1999;80:569-78.
38) Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann
G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo
K, Kerjaschki D. Angiosarcomas express mixed endothelial
phenotypes of blood and lymphatic capillaries: Podoplanin
as a specific marker for lymphatic endothelium. Am J Pathol.
1999;154:385-94.
39) Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new
marker of lymphatic endothelium, reacts with Kaposi’s sarcoma
and a subset of angiosarcomas. Mod Pathol. 2002;15:434-40.